BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

877 related articles for article (PubMed ID: 25804280)

  • 1. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Phospholipase A2 Receptor 1 and Anti-Cysteine Rich Antibodies, Domain Recognition and Rituximab Efficacy in Membranous Nephropathy: A Prospective Cohort Study.
    Ruggenenti P; Reinhard L; Ruggiero B; Perna A; Perico L; Peracchi T; Fidone D; Gennarini A; Benigni A; Cortinovis M; Hoxha E; Remuzzi G
    Am J Kidney Dis; 2024 May; 83(5):588-600.e1. PubMed ID: 38151224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative anti-phospholipase A2 receptor antibody status at three months predicts remission in primary membranous nephropathy.
    Stefan G; Stancu S; Zugravu A; Popa O; Zubidat D; Petre N; Mircescu G
    Ren Fail; 2022 Dec; 44(1):258-268. PubMed ID: 35172682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating anti-phospholipase A2 receptor antibodies as a diagnostic and prognostic marker in Greek patients with idiopathic membranous nephropathy - a retrospective cohort study.
    Provatopoulou S; Kalavrizioti D; Stangou M; Kouri MN; Kalliakmani P; Papasotiriou M; Papachristou E; Goumenos DS; Papagianni A
    Rom J Intern Med; 2019 Jun; 57(2):141-150. PubMed ID: 30864406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
    Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
    Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians.
    Ramachandran R; Kumar V; Kumar A; Yadav AK; Nada R; Kumar H; Kumar V; Rathi M; Kohli HS; Gupta KL; Sakhuja V; Jha V
    Nephrol Dial Transplant; 2016 Sep; 31(9):1486-93. PubMed ID: 26673907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy.
    Li C; Li H; Wen YB; Li XM; Li XW
    BMC Nephrol; 2018 Dec; 19(1):354. PubMed ID: 30541581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.
    Seitz-Polski B; Debiec H; Rousseau A; Dahan K; Zaghrini C; Payré C; Esnault VLM; Lambeau G; Ronco P
    J Am Soc Nephrol; 2018 Feb; 29(2):401-408. PubMed ID: 29114041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of long-term repeated rituximab treatment in refractory phospholipase A2 receptor-antibody-related membranous nephropathy.
    Zhang L; Chen M; Le W; Zhang M; Tu Y; Zuo K; Chen D; Wu Y; Li S; Zeng C; Cheng Z; Xie H
    Immunotherapy; 2022 Oct; 14(15):1237-1244. PubMed ID: 36097696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.
    Hoxha E; Thiele I; Zahner G; Panzer U; Harendza S; Stahl RA
    J Am Soc Nephrol; 2014 Jun; 25(6):1357-66. PubMed ID: 24610926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study.
    Zhou K; Zhou J; Zhou L; Xue J; Liu B; Zhang Z; Zhang X; Cai T; Shao S; Huang B; Zhang Y; Hu Z; Wang L; Liu X
    PLoS One; 2024; 19(5):e0302100. PubMed ID: 38718066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accelerating the Depletion of Circulating Anti-Phospholipase A2 Receptor Antibodies in Patients with Severe Membranous Nephropathy: Preliminary Findings with Double Filtration Plasmapheresis and Ofatumumab.
    Podestà MA; Gennarini A; Portalupi V; Rota S; Alessio MG; Remuzzi G; Ruggenenti P
    Nephron; 2020; 144(1):30-35. PubMed ID: 31336376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of anti-PLA₂R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy.
    Bech AP; Hofstra JM; Brenchley PE; Wetzels JF
    Clin J Am Soc Nephrol; 2014 Aug; 9(8):1386-92. PubMed ID: 25035272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Membranous Nephropathy.
    Couser WG
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):983-997. PubMed ID: 28550082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years.
    Pourcine F; Dahan K; Mihout F; Cachanado M; Brocheriou I; Debiec H; Ronco P
    PLoS One; 2017; 12(3):e0173201. PubMed ID: 28257452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
    Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ
    J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.